Speak with an expert

PHAD™ (MPLA Analogue)

Versatile and effective, PHAD acts as a TLR4 agonist to activate proinflammatory cytokines and antigen-specific effector cells. PHAD is the first synthetic analogue of monophosphoryl lipid A (MPLA) derived from Salmonella minnesota. MPLA has been shown to be safe and effective in stimulating Th-1 type immune responses. Avanti developed PHAD as a synthetic alternative to the bacterial-derived MPLA, given its desirable vaccine design profile of low reactogenicity and high efficacy.

indicates required field

First name

Please provide your first name

Last name

Please provide your last name

Please provide an email address

Country

County/Region

Company

Please provide your company name

Comments and questions